JP2022547558A5 - - Google Patents

Info

Publication number
JP2022547558A5
JP2022547558A5 JP2022515857A JP2022515857A JP2022547558A5 JP 2022547558 A5 JP2022547558 A5 JP 2022547558A5 JP 2022515857 A JP2022515857 A JP 2022515857A JP 2022515857 A JP2022515857 A JP 2022515857A JP 2022547558 A5 JP2022547558 A5 JP 2022547558A5
Authority
JP
Japan
Prior art keywords
item
approximately
compound
aqueous parenteral
crystal morphology
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022515857A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022547558A (ja
JP7719769B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/050511 external-priority patent/WO2021050956A1/en
Publication of JP2022547558A publication Critical patent/JP2022547558A/ja
Publication of JP2022547558A5 publication Critical patent/JP2022547558A5/ja
Priority to JP2025124956A priority Critical patent/JP2025137788A/ja
Application granted granted Critical
Publication of JP7719769B2 publication Critical patent/JP7719769B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022515857A 2019-09-11 2020-09-11 抗ウイルスプロドラッグ及びその医薬組成物 Active JP7719769B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025124956A JP2025137788A (ja) 2019-09-11 2025-07-25 抗ウイルスプロドラッグ及びその医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962898679P 2019-09-11 2019-09-11
US62/898,679 2019-09-11
PCT/US2020/050511 WO2021050956A1 (en) 2019-09-11 2020-09-11 Antiviral prodrugs and pharmaceutical compositions thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025124956A Division JP2025137788A (ja) 2019-09-11 2025-07-25 抗ウイルスプロドラッグ及びその医薬組成物

Publications (3)

Publication Number Publication Date
JP2022547558A JP2022547558A (ja) 2022-11-14
JP2022547558A5 true JP2022547558A5 (enExample) 2024-03-19
JP7719769B2 JP7719769B2 (ja) 2025-08-06

Family

ID=74866690

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2022515860A Active JP7703518B2 (ja) 2019-09-11 2020-09-11 抗ウイルスプロドラッグ及びその製剤
JP2022515857A Active JP7719769B2 (ja) 2019-09-11 2020-09-11 抗ウイルスプロドラッグ及びその医薬組成物
JP2025063311A Pending JP2025096427A (ja) 2019-09-11 2025-04-07 抗ウイルスプロドラッグ及びその製剤
JP2025124956A Pending JP2025137788A (ja) 2019-09-11 2025-07-25 抗ウイルスプロドラッグ及びその医薬組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022515860A Active JP7703518B2 (ja) 2019-09-11 2020-09-11 抗ウイルスプロドラッグ及びその製剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2025063311A Pending JP2025096427A (ja) 2019-09-11 2025-04-07 抗ウイルスプロドラッグ及びその製剤
JP2025124956A Pending JP2025137788A (ja) 2019-09-11 2025-07-25 抗ウイルスプロドラッグ及びその医薬組成物

Country Status (18)

Country Link
US (3) US20220323476A1 (enExample)
EP (2) EP4028019A4 (enExample)
JP (4) JP7703518B2 (enExample)
KR (2) KR20220066303A (enExample)
CN (4) CN114929236B (enExample)
AU (2) AU2020346908B2 (enExample)
BR (2) BR112022004424A2 (enExample)
CA (2) CA3150418A1 (enExample)
CL (4) CL2022000601A1 (enExample)
CO (2) CO2022005128A2 (enExample)
CR (2) CR20220110A (enExample)
DO (2) DOP2022000056A (enExample)
IL (4) IL290861B2 (enExample)
MX (4) MX2022002897A (enExample)
PE (2) PE20221036A1 (enExample)
PH (2) PH12022550528A1 (enExample)
UA (1) UA130229C2 (enExample)
WO (2) WO2021050961A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019014247A1 (en) 2017-07-11 2019-01-17 Gilead Sciences, Inc. COMPOSITIONS COMPRISING POLYMERASE RNA INHIBITOR AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS
CA3146679A1 (en) * 2019-07-27 2021-02-04 Brii Biosciences, Inc. Adenosine derivative and pharmaceutical composition comprising the same
KR20220066303A (ko) * 2019-09-11 2022-05-24 더 스크립스 리서치 인스티튜트 항바이러스 전구약물 및 이의 약제학적 조성물
JP7703538B2 (ja) * 2019-12-09 2025-07-07 ヴィーブ、ヘルスケア、カンパニー カボテグラビルを含んでなる医薬組成物
JP2023512656A (ja) 2020-01-27 2023-03-28 ギリアード サイエンシーズ， インコーポレイテッド ＳＡＲＳ ＣｏＶ－２感染を治療するための方法
KR20220153619A (ko) 2020-03-12 2022-11-18 길리애드 사이언시즈, 인코포레이티드 1'-시아노 뉴클레오사이드의 제조 방법
WO2021188959A1 (en) * 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
CA3172483A1 (en) 2020-04-06 2021-10-14 Scott Ellis Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
TW202203941A (zh) 2020-05-29 2022-02-01 美商基利科學股份有限公司 瑞德西韋之治療方法
PE20230618A1 (es) 2020-06-24 2023-04-14 Gilead Sciences Inc Analogos de nucleosido de 1'-ciano y usos de los mismos
IL300453A (en) 2020-08-27 2023-04-01 Gilead Sciences Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
EP4281083A4 (en) 2021-01-25 2025-01-01 Brii Biosciences, Inc. COMBINATION THERAPY FOR HIV WITH ADENOSINE DERIVATIVE AND CAPSID INHIBITORS
EP4281081A4 (en) 2021-01-25 2025-05-14 Brii Biosciences, Inc. ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF
MX2023010797A (es) * 2021-03-16 2023-09-27 Scripps Research Inst Profarmacos antivirales de entecavir (etv) y formulaciones de los mismos.
KR20240154647A (ko) 2022-03-02 2024-10-25 길리애드 사이언시즈, 인코포레이티드 바이러스성 감염 치료를 위한 화합물 및 방법
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof
CN121358747A (zh) 2023-06-27 2026-01-16 吉利德科学公司 核苷逆转录酶易位抑制剂的固体形式
CN121419986A (zh) * 2023-06-27 2026-01-27 吉利德科学公司 用于制备抗病毒前药的方法和中间体
FI20245041A1 (en) 2024-01-17 2025-07-18 Metso Finland Oy Precipitation of calcium compounds in liquid extraction systems

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283067A (en) 1987-01-30 1994-02-01 Ciba-Geigy Corporation Parenteral suspensions
US5192749A (en) 1990-05-21 1993-03-09 Syntex (U.S.A.) Inc. 4'-substituted nucleosides
FR2694693B1 (fr) * 1992-07-28 1994-10-28 Abrax Bio Labs Sa Composition pharmaceutique à base de flavopéréirine et son utilisation dans un traitement contre le virus VIH.
ATE250622T1 (de) 1999-05-12 2003-10-15 Yamasa Corp 4'-c-ethynyl-pyrimidine nukleoside
US6576619B2 (en) * 1999-05-24 2003-06-10 Cv Therapeutics, Inc. Orally active A1 adenosine receptor agonists
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
CA2502109C (en) * 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
EA200800932A1 (ru) 2005-09-26 2008-10-30 Фармассет, Инк. Модифицированные 4`-нуклеозиды в качестве противовирусных агентов
CN100532388C (zh) 2007-07-16 2009-08-26 郑州大学 2’-氟-4’-取代-核苷类似物、其制备方法及应用
US20090274686A1 (en) 2008-05-02 2009-11-05 Yat Sun Or Nucleoside phosphonate derivatives
NZ593649A (en) 2008-12-23 2013-11-29 Gilead Pharmasset Llc Nucleoside analogs
WO2013090420A2 (en) 2011-12-12 2013-06-20 Catabasis Pharmaceuticals, Inc. Fatty acid antiviral conjugates and their uses
WO2015143712A1 (en) 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
CA3182565A1 (en) 2015-03-06 2016-09-15 Atea Pharmaceuticals, Inc. .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
MX391226B (es) 2015-09-23 2025-03-21 Merck Sharp & Dohme Llc Inhibidores de transcriptasa inversa de nucleosido 4'-substituido y preparaciones de los mismos.
US10745428B2 (en) * 2015-12-10 2020-08-18 Idenix Pharmaceuticals Llc Antiviral phosphodiamide prodrugs of tenofovir
FR3053281B1 (fr) 2016-06-30 2020-03-27 Banque De France Procede de fabrication d'un document de securite presentant un signe de securite a contraste de brillance
US10185393B2 (en) 2017-04-03 2019-01-22 Facebook Technologies, Llc Waveguide display with spatially switchable grating
PT3706762T (pt) * 2017-12-07 2024-12-05 Univ Emory N4-hidroxicitidina e derivados e utilizações antivirais relacionadas com os mesmos
US20190185508A1 (en) 2017-12-15 2019-06-20 Merck Sharp & Dohme Corp. Deuterated nucleoside reverse transcriptase inhibitors
EP3762396A1 (en) 2018-03-07 2021-01-13 GlaxoSmithKline Intellectual Property (No.2) Limited Compounds useful in hiv therapy
AU2019317810A1 (en) 2018-08-09 2021-02-25 Glaxosmithkline Intellectual Property (No.2) Limited Compounds useful in HIV therapy
US11572595B2 (en) * 2018-12-31 2023-02-07 Roche Molecular Systems, Inc. Non-replicative transduction particles with one or more non-native tail fibers and transduction particle-based reporter systems
CN113811360A (zh) 2019-03-06 2021-12-17 葛兰素史密斯克莱知识产权（第2 号）有限公司 用于hiv治疗的化合物
CA3146679A1 (en) 2019-07-27 2021-02-04 Brii Biosciences, Inc. Adenosine derivative and pharmaceutical composition comprising the same
KR20220066303A (ko) 2019-09-11 2022-05-24 더 스크립스 리서치 인스티튜트 항바이러스 전구약물 및 이의 약제학적 조성물
CN121358747A (zh) 2023-06-27 2026-01-16 吉利德科学公司 核苷逆转录酶易位抑制剂的固体形式
CN121419986A (zh) 2023-06-27 2026-01-27 吉利德科学公司 用于制备抗病毒前药的方法和中间体

Similar Documents

Publication Publication Date Title
JP2022547558A5 (enExample)
JP7719769B2 (ja) 抗ウイルスプロドラッグ及びその医薬組成物
JP5140222B2 (ja) 低用量エンテカビル製剤およびその使用
JP3133345B2 (ja) Ｈｉｖに対して活性な連結環状ポリアミン
JP2023543059A5 (enExample)
JP2022547978A5 (enExample)
JP2023512656A5 (enExample)
JP2022505841A5 (enExample)
JP2004509061A5 (enExample)
RU2002120922A (ru) Нуклеозидные аналоги с карбоксамидин-модифицированным моноциклическим основанием
KR20150093819A (ko) 약제 조성물
ES2324009B1 (es) Composicion farmaceutica de liberacion sostenida de somatostatina o un analogo suyo.
JP2022527556A5 (enExample)
JP2020507589A5 (enExample)
JP2022501370A5 (enExample)
JP2024507788A5 (enExample)
JP2007501284A5 (enExample)
JP2024503723A5 (enExample)
WO2014035945A1 (en) Pharmaceutical compositions
WO1996038173A1 (en) Brain edema inhibitor
JP2022548652A (ja) コアタンパク質アロステリックモジュレータを使用してｈｂｖ感染を処置する方法
JP2022521119A5 (enExample)
JP2021501202A5 (enExample)
JP2022547324A5 (enExample)
JP2024507550A5 (enExample)